Leonteq Securities AG’s Atea Pharmaceuticals AVIR Stock Holding History

Leonteq Securities AG’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-5,000	Closed	-$16.8K	–	1236
2024 Q4	$16.8K	Hold	5,000	–	–	﹤0.01%	996
2024 Q3	$16.8K	Hold	5,000	–	–	﹤0.01%	928
2024 Q2	$16.6K	Hold	5,000	–	–	﹤0.01%	938
2024 Q1	$20.2K	Hold	5,000	–	–	﹤0.01%	926
2023 Q4	$15.3K	Hold	5,000	–	–	﹤0.01%	957
2023 Q3	$15K	Sell	5,000 -2,000	-29%	-$6.8K	﹤0.01%	980
2023 Q2	$26.2K	Buy	7,000 +2,000	+40%	+$7.49K	﹤0.01%	936
2023 Q1	$16.8K	Buy	5,000 +3,000	+150%	+$12.2K	﹤0.01%	942
2022 Q4	$9.62K	Hold	2,000	–	–	﹤0.01%	1064
2022 Q3	$11.4K	Hold	2,000	–	–	﹤0.01%	1041
2022 Q2	$14.2K	Buy	2,000 +1,000	+100%	+$6.83K	﹤0.01%	1032
2022 Q1	$7.22K	Hold	1,000	–	–	﹤0.01%	1144
2021 Q4	$8.94K	Buy	1,000 +500	+100%	+$7.79K	﹤0.01%	1164
2021 Q3	$17.5K	Sell	500 -200	-29%	-$5.55K	﹤0.01%	1010
2021 Q2	$15K	Buy	700 +600	+600%	+$18K	﹤0.01%	972
2021 Q1	$6.17K	Buy	+100	New	+$6.76K	﹤0.01%	941

Other funds holding AVIR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Leonteq Securities AG's AVIR Position: Q1 2025 in Review

Leonteq Securities AG sold out of Atea Pharmaceuticals (AVIR) in Q1 2025, closing a stake of 5,000 shares — an estimated $16.8K sold.

Leonteq Securities AG first reported a position in AVIR in Q1 2021 and held it in 16 quarters. The position peaked at $26.2K in Q2 2023. 103 funds tracked by Wall St. Rank hold AVIR as of Q1 2025.

Leonteq Securities AG reported no remaining Atea Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Leonteq Securities AG sold 5,000 Atea Pharmaceuticals shares in Q1 2025, an estimated $16.8K.
Leonteq Securities AG first reported a position in Atea Pharmaceuticals in Q1 2021 and held it in 16 quarters.
Leonteq Securities AG's Atea Pharmaceuticals position peaked at $26.2K in Q2 2023.
103 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2025.

Based on Leonteq Securities AG's 13F filing for Q1 2025, filed 23 Feb 2026.